Legend Biotech Corporation (LEGN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Legend Biotech Corporation (“Legend” or “the Company”) (NASDAQ: LEGN). Investors who purchased Legend securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Legend has violated federal securities laws.
On November 28, 2023, the U.S. Food and Drug Administration (“FDA”) announced that it “is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action” after “receiving reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.” The FDA’s press release listed Legend’s Carvykti (ciltacabtagene autoleucel) as among the approved products in the class of products at issue. On this news, Legend’s stock price fell sharply during intraday trading on November 28, 2023.
If you are aware of any facts relating to this investigation or purchased Legend securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.